|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||6.45 - 6.99|
|52 Week Range||3.33 - 10.45|
|Beta (3Y Monthly)||2.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Generic pharmaceutical products provider Lannett Company (LCI) is a puzzle.Lannett shares jumped as much as 50% today, before trimming back some gains to trade up about 40%. Why? Your guess is as good as anybody else’s.SunTrust analyst Gregg Gilbert believes "management has been doing the right things to diversify the business and grow out of the levo trough." However, the analyst remains sidelined on the stock "pending greater visibility on the durability and profitability of the evolving portfolio and strategy to deal with the large debt load." The investigation into generic drug price fixing in the industry gives the analyst another reason to be worried about. But overall, the analyst believes that "this risk has taken more out of generic market caps than seems reasonable."Gilbert rates Lannett stock a Hold along with a $9.00 price target, which implies nearly 7% upside from current levels. (To watch Gilbert's track record, click here)BMO analyst Gary Nachman believes Lannett stock is worth $10 a share, the highest price target of any of the analysts recommending the stock today, though he rates the stock Neutral.Nachman stated, "LCI is executing well trying to manage through Levo loss and base erosion (typically mid-single digits, although some upside there in F2019). New product launches are expected to generate ~$75mm annually (F2019 on track for that), with about half expected from internal R&D and half from inlicensed products. Recently approved AB-rated Methylphenidate with partner Andor (launch late-June) and Thalidomide (addressing CRL, expected launch C2020) should be important contributors. Numbrino approval is expected by year-end, but LCI will cease unapproved C-topical sales ($3mm/qtr.) in August. On cost savings, LCI has completed all necessary actions and will finalize Cody Labs transition soon. LCI is proactively managing debt load (repurchased $24mm in open market, cash ~$205mm) and is confident in maintaining covenant compliance on 2020 debt."Ultimately, TipRanks reveals LCI as a stock that has not drawn a vote of confidence among Wall Street opinion. Out of 5 analysts polled in the last 12 months, all 5 rate the stock Hold/Neutral. Worthy of note, the 12-month average price target stands at $8.33, which aligns evenly with where the stock is currently trading. (See LCI's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * Hedge Fund Legend Jim Simons Pours Money Into Aurora Cannabis (ACB) and Aphria (APHA) Stocks * 3 Healthcare Stocks to Fight Off the Market Flu * GrowGeneration (GRWG) Could Grow at Annual Rate of 100% * Is Apple (AAPL) Stock a Good Play With Tariff Delay?
Shares of generic-drug manufacturer Lannett Company Inc. shot up 40% in Monday afternoon trade. The company has not released any news that would account for the stock move, a spokesman for the company said. However, Lannet stock's short interest stood at at 20.66 million shares at the end of June, equal to 74.3% of the company's public float of 27.8 million shares. Ihor Dusaniwsky,managing director for predictive analytics at S3 Partners, a company that tracks short interest, said the move was not caused by a short squeeze, although it could trigger one if the stock keeps rallying. Short positions were down about $128,000 year-to-date, through Friday. "Shorts have taken a good stomach punch today, they're down $46.2 million," he said. "They are definitely a candidate for a short squeeze after today." Shares of Lannett have gained 67.9% in the year to date, while the S&P 500 has gained 19.2%.
On Tuesday morning, Benzinga Pro subscribers received two options alerts related to Lannett. At 9:36 a.m., a trader bought 854 Lannett call options at a $7.50 strike price that expire on Sept. 20. At 9:42 a.m., likely the same trader bought another 752 Sept. 20 $7.50 Lannett call options at the ask price of 45.1 cents.
The federal agency's ruling means its review of Lannett's new drug application for a topical cocaine hydrocholride product can continue.
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
The Northeast Philadelphia generic drug maker said it received written notice from various state Attorneys General that they intend to bring claims alleging price fixing and anti-competitive behavior involving more drug products.
Quarterly operating results were pretty good, but the business disclosed that it may face a lawsuit along with other makers of generic drugs.
Lannett (LCI) delivered earnings and revenue surprises of 9.68% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Philadelphia-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 68 cents per share. The results beat Wall ...
Lannett Co (NYSE: LCI ) unveils its next round of earnings this Monday, May 6. Get prepared with Benzinga's ultimate preview for Lannett's third-quarter earnings. Earnings and Revenue Lannett EPS is expected ...
Lannett Co. Inc. said Tuesday it plans to launch a generic version of the attention deficit hyperactivity disorder drug Concerta later this quarter. The launch is the result of a licensing deal the Northeast Philadelphia generic drug company signed in August with Andor Pharmaceuticals of Florida for its extended-release methylphenidate hydrochloride tablets. Methylphenidate hydrochloride is the active ingredient in Concerta, which is marketed by a subsidiary of Johnson & Johnson.
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. Anyone who held Lannett Company, Inc. (NYSE:LCI) for five years would...